Stock comparison
ResMed
Theravance Biopharma
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
TBPH
Theravance Biopharma
Market cap
$843.92M
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RMD | TBPH | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 53D | RMD |
| Benjamin Graham | 75B | 51D | RMD |
| Philip Fisher | 75B | 45D | RMD |
| Peter Lynch | 58C | 53C | RMD |
| Joel Greenblatt | 47D | 36D | RMD |
| Charlie Munger | 69B | 39D | RMD |
| Terry Smith | 73B | 56C | RMD |
Side-by-side metrics
| Metric | RMD | TBPH |
|---|---|---|
| Market cap | $30.18B | $843.92M |
| P/E (TTM) | 19.6x | 7.4x |
| EV/EBIT | 17.1x | - |
| ROIC (TTM) | 19.63% | -1.32% |
| Gross margin | 61.69% | 104.1% |
| Net margin | 27.44% | 104.34% |
| Revenue CAGR 5y | 12.64% | 18.06% |
| EPS CAGR 5y | 30.73% | - |
| Debt / Equity | 0.1x | 0.3x |
| Dividend yield | 1.14% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RMD leads on
- ROIC (TTM)19.63%vs -1.32%+107%
- Dividend yield1.14%vs 0.0%+100%
- Market cap$30.18Bvs $843.92M+97%
- Debt / Equity0.1xvs 0.3x+49%
TBPH leads on
- EV/EBIT-vs 17.1x+136%
- Net margin104.34%vs 27.44%+74%
- P/E (TTM)7.4xvs 19.6x+63%
- Gross margin104.1%vs 61.69%+41%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.